[go: up one dir, main page]

MX9302195A - Derivados de indol, procedimiento para su reparacion y composicion farmaceutica que los comprende. - Google Patents

Derivados de indol, procedimiento para su reparacion y composicion farmaceutica que los comprende.

Info

Publication number
MX9302195A
MX9302195A MX9302195A MX9302195A MX9302195A MX 9302195 A MX9302195 A MX 9302195A MX 9302195 A MX9302195 A MX 9302195A MX 9302195 A MX9302195 A MX 9302195A MX 9302195 A MX9302195 A MX 9302195A
Authority
MX
Mexico
Prior art keywords
derivatives
indol
repair
procedure
pharmaceutical composition
Prior art date
Application number
MX9302195A
Other languages
English (en)
Inventor
Alfredo Cugola
Giovanni Gavirachi
Simone Giacobre
Original Assignee
Glaxo Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Spa filed Critical Glaxo Spa
Publication of MX9302195A publication Critical patent/MX9302195A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Esta invención se refiere a nuevos derivados de indol, a los procedimientos para su preparación a las composiciones farmacéuticas que los contienen y a su uso en la medicina. En particular, se refiere a derivados de indol que son antagonistas potentes y específicos de los aminoácidos excitadores.
MX9302195A 1992-04-16 1993-04-15 Derivados de indol, procedimiento para su reparacion y composicion farmaceutica que los comprende. MX9302195A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929208492A GB9208492D0 (en) 1992-04-16 1992-04-16 Heterocyclic compounds

Publications (1)

Publication Number Publication Date
MX9302195A true MX9302195A (es) 1994-03-31

Family

ID=10714220

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9302195A MX9302195A (es) 1992-04-16 1993-04-15 Derivados de indol, procedimiento para su reparacion y composicion farmaceutica que los comprende.

Country Status (41)

Country Link
US (4) US5374649A (es)
EP (1) EP0568136A1 (es)
JP (2) JPH07505407A (es)
KR (1) KR100264114B1 (es)
CN (1) CN1042331C (es)
AP (1) AP480A (es)
AT (1) AT403917B (es)
AU (1) AU666927B2 (es)
BE (1) BE1006343A5 (es)
BG (1) BG62136B1 (es)
BR (1) BR1100323A (es)
CA (3) CA2094075A1 (es)
CH (1) CH685630A5 (es)
CY (1) CY2038B1 (es)
CZ (1) CZ285799B6 (es)
DK (1) DK169890B1 (es)
ES (1) ES2105924B1 (es)
FI (1) FI106198B (es)
FR (1) FR2690919B1 (es)
GB (2) GB9208492D0 (es)
GE (1) GEP19991704B (es)
GR (1) GR1001619B (es)
HK (1) HK95797A (es)
HU (2) HU217964B (es)
IL (1) IL105412A (es)
IS (1) IS3994A (es)
IT (1) IT1265325B1 (es)
LU (1) LU88248A1 (es)
MX (1) MX9302195A (es)
MY (1) MY112232A (es)
NO (1) NO301879B1 (es)
NZ (1) NZ247413A (es)
OA (1) OA10103A (es)
PL (1) PL176451B1 (es)
RO (1) RO113242B1 (es)
RU (1) RU2129544C1 (es)
SE (1) SE504336C2 (es)
SK (1) SK281941B6 (es)
TW (1) TW224457B (es)
WO (1) WO1993021153A1 (es)
ZA (1) ZA932642B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9304500D0 (en) * 1993-03-05 1993-04-21 Glaxo Spa Heterocyclic compounds
KR100314482B1 (ko) * 1993-05-27 2002-02-28 메렐 파마슈티칼스 인크. 3-(인돌-3-일)프로페노산유도체
US5519048A (en) * 1993-05-27 1996-05-21 Merrell Pharmaceuticals Inc. 3-(indol-3-yl)-propenoic acid derivatives and pharmaceutical compositions thereof
GB9319243D0 (en) * 1993-09-17 1993-11-03 Glaxo Spa Heterocyclic compounds
GB9321221D0 (en) * 1993-10-14 1993-12-01 Glaxo Spa Heterocyclic compounds
TW280819B (es) * 1993-11-17 1996-07-11 Sumitomo Pharma
US5563157B1 (en) 1994-10-31 1999-02-02 Hoecst Marion Roussel Inc Heterocycle substituted propenoic acid derivatives and pharmaceutical compositions thereof
GB9502695D0 (en) * 1995-02-11 1995-03-29 Glaxo Spa Pharmaceutical composition
GB9504361D0 (en) * 1995-03-04 1995-04-26 Glaxo Spa Heterocyclic compounds
US6030968A (en) * 1996-09-17 2000-02-29 The Regents Of The University Of California Positive AMPA receptor modulation to enhance brain neurotrophic factor expression
DE69734594T2 (de) * 1996-09-30 2006-07-06 Aventis Pharmaceuticals Inc. Nmda (n-methyl-d-aspartate) antagonists
US5922752A (en) * 1997-06-11 1999-07-13 Hoechst Marion Roussell, Inc. NMDA (n-methyl-d-aspartate) antagonists
KR100440553B1 (ko) * 1998-03-26 2004-07-15 후지사와 야꾸힝 고교 가부시키가이샤 서방성 제제
WO2003039540A2 (en) * 2001-11-09 2003-05-15 Sepracor Inc. D-amino acid oxidase inhibitors for learning and memory
US7582657B2 (en) * 2001-12-10 2009-09-01 Amgen Inc. Vanilloid receptor ligands and their use in treatments
PA8579701A1 (es) * 2002-08-23 2005-05-24 Pfizer Prod Inc Profarmaco inhibidor de beta-lactamasa
DE10306202A1 (de) * 2003-02-13 2004-08-26 Grünenthal GmbH Arzneimittel enthaltend substituierte 2-Aryl-Aminoessigsäure-Verbindungen und/oder substituierte 2-Heteroaryl-Aminoessigsäure-Verbindungen
EP1636240A1 (en) * 2003-06-05 2006-03-22 Pfizer Products Inc. Beta-lactamase inhibitor prodrug
JP4864719B2 (ja) * 2003-11-26 2012-02-01 ファイザー・プロダクツ・インク Ｇｓｋ−３インヒビターとしてのアミノピラゾール誘導体
US7488747B2 (en) * 2003-12-29 2009-02-10 Sepracor Inc. Pyrrole and pyrazole DAAO inhibitors
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
EP1904066B1 (en) 2005-07-06 2018-05-23 Sunovion Pharmaceuticals Inc. COMBINATIONS OF ESZOPICLONE AND TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE OR TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE, for treating MENOPAUSE, perimenopause AND COGNITIVE DISORDERS
CA2636275C (en) 2006-01-06 2013-02-12 Sepracor Inc. Tetralone-based monoamine reuptake inhibitors
CN101394847B (zh) 2006-01-06 2017-05-24 塞普拉柯公司 作为单胺重摄取抑制剂的环烷基胺类
JP5377285B2 (ja) 2006-03-31 2013-12-25 サノビオン ファーマシューティカルズ インク キラルアミドおよびキラルアミンの調製
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
MX2009007410A (es) * 2007-01-18 2009-09-09 Sepracor Inc Inhibidores de d-aminoacido oxidasa.
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
CN103936605B (zh) 2007-05-31 2017-09-01 赛诺维信制药公司 苯基取代的环烷胺作为一元胺再摄取抑制剂
US20090247644A1 (en) * 2008-03-28 2009-10-01 Forest Laboratories Holdings Limited Memantine formulations
US20100120740A1 (en) * 2008-08-07 2010-05-13 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US20110319463A1 (en) * 2009-03-10 2011-12-29 Saten Pharamaceuticals Co., Ltd. Preventive or therapeutic agents for optic nerve disorders comprising 4,6-dichloro-1h-indole-2-carboxylic acid derivatives or salts thereof as active ingredients
US20110034434A1 (en) * 2009-08-07 2011-02-10 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
IL248567B (en) 2014-04-30 2022-08-01 Univ Nat Taiwan Use of known compounds as d-amino acid oxidase inhibitors
IL307576B1 (en) 2016-09-14 2025-02-01 Yufeng Jane Tseng History of new modified benzimidazoles as D-amino acid oxidase (DAAO) inhibitors
JP7305560B2 (ja) 2017-06-12 2023-07-10 グリテック， エルエルシー Ｎｍｄａアンタゴニスト及びｄ２／５ｈｔ２ａ又は選択的５ｈｔ２ａアンタゴニストによるうつ病の治療
CN112707874A (zh) * 2020-12-29 2021-04-27 广东中科药物研究有限公司 一种抗病毒化合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3010971A (en) * 1960-08-04 1961-11-28 Smith Kline French Lab Cyclopropylamine derivatives and processes for their preparation
DK500285A (da) * 1984-11-02 1986-05-03 Glaxo Group Ltd Cephalosporinantibiotika
US4960786A (en) * 1989-04-24 1990-10-02 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
JPH0347123A (ja) * 1989-05-05 1991-02-28 G D Searle & Co インドール―２―カルボキシレート化合物類を含有するｃｎｓ疾患治療用組成物
KR0178469B1 (ko) * 1990-07-16 1999-03-20 메이나드 알. 존슨 흥분성 아미노산 길항제
US5284862A (en) * 1991-03-18 1994-02-08 Warner-Lambert Company Derivatives of 2-carboxyindoles having pharmaceutical activity
US5145845A (en) * 1991-05-14 1992-09-08 Warner-Lambert Co. Substituted 2-carboxylindoles having pharmaceutical activity

Also Published As

Publication number Publication date
CY2038B1 (en) 1998-04-30
AP480A (en) 1996-03-22
MY112232A (en) 2001-05-31
SE504336C2 (sv) 1997-01-13
CA2094073A1 (en) 1993-10-17
CN1042331C (zh) 1999-03-03
CZ254394A3 (en) 1995-07-12
TW224457B (es) 1994-06-01
FI944800A0 (fi) 1994-10-12
NO943913L (no) 1994-12-14
AU666927B2 (en) 1996-02-29
US5510367A (en) 1996-04-23
JPH07505407A (ja) 1995-06-15
ATA75293A (de) 1997-11-15
CN1085212A (zh) 1994-04-13
CA2094075A1 (en) 1993-10-17
HUT70526A (en) 1995-10-30
NZ247413A (en) 1995-12-21
SK281941B6 (sk) 2001-09-11
HU9402975D0 (en) 1995-02-28
GB2266091B (en) 1995-08-09
US5374648A (en) 1994-12-20
CA2094076A1 (en) 1993-10-17
ITRM930236A1 (it) 1994-10-15
AP9300524A0 (en) 1993-04-30
NO301879B1 (no) 1997-12-22
WO1993021153A1 (en) 1993-10-28
BG99111A (bg) 1995-05-31
OA10103A (en) 1996-12-18
HU217964B (hu) 2000-05-28
CH685630A5 (fr) 1995-08-31
DK43193A (da) 1993-10-17
IL105412A0 (en) 1993-08-18
DK169890B1 (da) 1995-03-27
DK43193D0 (da) 1993-04-15
HK95797A (en) 1997-08-08
RU2129544C1 (ru) 1999-04-27
IS3994A (is) 1993-10-17
GB9307808D0 (en) 1993-06-02
GEP19991704B (en) 1999-08-05
GB9208492D0 (en) 1992-06-03
GR1001619B (el) 1994-07-29
US5373018A (en) 1994-12-13
BR1100323A (pt) 2000-06-27
FI944800A (fi) 1994-10-12
BE1006343A5 (fr) 1994-07-26
NO943913D0 (no) 1994-10-14
PL176451B1 (pl) 1999-05-31
AU3692393A (en) 1993-10-21
EP0568136A1 (en) 1993-11-03
ITRM930236A0 (it) 1993-04-15
IL105412A (en) 1998-02-22
IT1265325B1 (it) 1996-10-31
SK124194A3 (en) 1995-05-10
BG62136B1 (bg) 1999-03-31
ES2105924A1 (es) 1997-10-16
FI106198B (fi) 2000-12-15
GB2266091A (en) 1993-10-20
FR2690919A1 (fr) 1993-11-12
LU88248A1 (fr) 1994-03-01
SE9301241D0 (sv) 1993-04-15
KR100264114B1 (ko) 2000-11-01
ZA932642B (en) 1994-01-10
ES2105924B1 (es) 1998-07-01
SE9301241L (sv) 1993-10-17
US5374649A (en) 1994-12-20
FR2690919B1 (fr) 1995-05-05
RO113242B1 (ro) 1998-05-29
AT403917B (de) 1998-06-25
JPH0649027A (ja) 1994-02-22
CZ285799B6 (cs) 1999-11-17
RU94045915A (ru) 1996-09-10
HU211826A9 (en) 1995-12-28

Similar Documents

Publication Publication Date Title
MX9302195A (es) Derivados de indol, procedimiento para su reparacion y composicion farmaceutica que los comprende.
MX9300261A (es) Derivados de 1,5-benzodiacepina, proceso para su preparacion y composicion farmaceutica que los contiene.
ES2144192T3 (es) Nuevos derivados de 1-fenil-2-dimetil-amino-metil-ciclohexan-1-ol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR062931A2 (es) Compuestos que se enlazan a y activan un receptor de la trombopoyetina , composicones farmaceuticas que los contienen y su uso para la preparacion de medicamentos
MX9400166A (es) Microesferas de proteina vegetal, hidrolizada, modificada y metodos para su preparacion y su uso.
ES2059789T3 (es) Esteroides sustituidos con acido fosfinico como inhibidores de la esteroide-5 alfa-reductasa.
HN1998000157A (es) Agonistas de prostaglandinas
CO4930259A1 (es) Derivados 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen
MX19448A (es) Procedimiento para la prreparacion de compuestos antagonistas de los receptores de aminoacidos excitadores; compuestos obtenidos y composicion farmaceutica que los incluye.
ES2191320T3 (es) Derivados de piperazina y su uso como agentes anti-inflamatorios.
MX9301929A (es) Derivados de pirimidina y procedimientos para su preparacion.
ES502644A0 (es) Procedimiento de obtencion de nuevos derivados de la vin- blastina
ES2044870T3 (es) Un procedimiento para la preparacion de nuevos agentes antihipertensivos.
UY24986A1 (es) Compuestos
MX9201356A (es) Derivados de piperidina, procedimiento para su preparacion y composicion farmaceutica que los contiene.
ES2178055T3 (es) Derivados aminicos substituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
HUT67237A (en) Excitatory amino acid antagonists indole derivatives, their preparation and pharmaceutical compositions comprising them
ECSP941120A (es) Derivados de 1,5 benzodiazepina
MX9300399A (es) Derivados heterotriciclicos.
AR002704A1 (es) 2-(2-n-alcoxifenil)-purin-6-onas 9-sustituidas, procedimiento para su preparacion, composiciones farmaceuticas que las contienen y su uso parapreparar composiciones farmaceuticas.
CR6398A (es) Antagonistas de 5ht1 para terapia antidepresiva
MX9301157A (es) Derivados de bencimidazolona, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
AR002017A1 (es) Derivados de fenil-4-tiazoles substituidos, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y derivados defenil-4-tiazoles substituidos empleados en dicho procedimiento.
MX9303574A (es) Compuestos heterociclicos que son inhibidores de la enzima aromatasa, proceso para su preparacion ycomposiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees